A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Percentage of Participants Achieving 24-Month Sustained MRD-Negative CR
Percentage of Participants with Very Good Partial Response (VGPR) or Better
Percentage of Participants with Complete Response (CR) or Better
Percentage of Participants with Overall Response (ORR)
Show 16 moreShow less
Percentage of Participants with Overall MRD-Negative CR
Percentage of Participants Achieving 12-Month Sustained MRD-Negative CR
Progression-Free Survival 2 (PFS2)
Number of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
Number of Participants With Adverse Events by Severity
Number of Participants with Significant Abnormalities in Laboratory Parameters
Change from Baseline in Health-related Quality of Life (HRQoL), Symptoms and Functioning Using the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Scores
Change from Baseline in HRQoL, Symptoms and Functioning Using the EORTC QLQ C30 Scale Scores
Change from Baseline in HRQoL, Symptoms and Functioning Using European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Scale Scores
Time to Worsening in HRQoL, Symptoms and Functioning Using the MySIm-Q Scale Scores
Time to Worsening in HRQoL, Symptoms and Functioning Using the EORTC-QLQ-C30 Scale Scores
Time to Worsening in HRQoL, Symptoms and Functioning Using the EQ-5D-5L Scale Scores
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the MySIm-Q Scale Scores
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the EORTC-QLQ-C30 Scale Scores
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the EQ-5D-5L Scale Scores
Percentage of Participants Who Report Side Effect Burden as Assessed by the European Organization for Research and Treatment of Cancer Item List (EORTC IL) 46
Arms and interventions
Arm A: Ramantamig and Daratumumab (Ramantamig-D)Experimental
Participants will receive subcutaneous (SC) dose of ramantamig-D.
Arm B: DVRd+ HDT+ ASCT+ DRActive comparator
Participants will receive Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) along with High-Dose Therapy (HDT), Autologous Stem Cell Transplantation (ASCT) and Daratumumab and Lenalidomide (DR) maintenance for 2 years or until progressive disease (PD) or intolerable toxicity whichever occurs first. Participants will have the option to continue lenalidomide and/or daratumumab maintenance therapy beyond 2 years, until PD, at the investigator's discretion and sponsor approval.
